Following on from the discussion about the US biosimilar landscape in the previous episode, CBPartners’ experts explore the trends and dynamics of the biosimilar market ex-USA – across the EU, Latin America and Asia Pacific regions, with a focus on:

•  Biosimilar availability and uptake in each region
•  Key barriers limiting biosimilar approval and uptake    
• Biosimilar manufacturer strategies to ensure successful launch 

As the costs of biologic drugs increase, biosimilars have emerged as an appealing option for controlling costs and expanding access to treatment. While the uptake of biosimilars in the USA started off slowly, it has since gained a rapid pace. 

In the first of a multi-part biosimilar series, this episode will explore the evolving biosimilar landscape, including the opportunities and barriers for uptake, as well as the future outlook for biosimilars in the USA. Topics covered include: 

• Current biosimilar landscape and key players 
• Top barriers and incentives to biosimilar uptake in the USA 

During the 2020 US Presidential Election, several campaign promises, policies, and healthcare reforms were presented by both the Republican and Democratic parties. Since winning the election, President Biden, his new administration, and the new democrat-controlled congress have prioritized  efforts to combat the COVID-19 pandemic. However, the administration has not been idle in targeting broader changes promised on the campaign trail, including meaningful expansions to the Affordable Care Act layered into their landmark COVID-19 relief package. 

Uncertainty remains, but more policy proposals, executive orders, and bills are expected in the coming years of the Biden administration.  

This episode, which kicks off season two of CBPartners’ Pharma Take-away, discusses the possible evolution of healthcare and healthcare policy in the United States, and explores the changes we may expect over the next few years as a result of the party transition. Topics covered include: 

• Healthcare-related Trump-era executive orders and review proposals 
• Drug pricing 
• Potential reforms and policy goals